BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 35386697)

  • 41. Over-expression of TRPM8 is associated with poor prognosis in urothelial carcinoma of bladder.
    Xiao N; Jiang LM; Ge B; Zhang TY; Zhao XK; Zhou X
    Tumour Biol; 2014 Nov; 35(11):11499-504. PubMed ID: 25128062
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Correlation between messenger RNA expression and protein expression of immune checkpoint-associated molecules in bladder urothelial carcinoma: A retrospective study.
    Le Goux C; Damotte D; Vacher S; Sibony M; Delongchamps NB; Schnitzler A; Terris B; Zerbib M; Bieche I; Pignot G
    Urol Oncol; 2017 May; 35(5):257-263. PubMed ID: 28291636
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prognostic and clinicopathological significance of PD-L1 and tumor infiltrating lymphocytes in hypopharyngeal squamous cell carcinoma.
    Hu C; Tian S; Lin L; Zhang J; Ding H
    Oral Oncol; 2020 Mar; 102():104560. PubMed ID: 31923855
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Increased PD-L1 expression in high-grade bladder cancer with squamous cell differentiation in Bulgarian and French patients' samples.
    Gulinac M; Dikov D; Velikova T; Belovezhdov V
    Ann Diagn Pathol; 2020 Dec; 49():151640. PubMed ID: 33069081
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Crude mortality and loss of life expectancy of patients diagnosed with urothelial carcinoma of the urinary bladder in Norway.
    Andreassen BK; Myklebust TÅ; Haug ES
    Scand J Urol; 2017 Feb; 51(1):38-43. PubMed ID: 28084860
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Concordance of PD-L1 expression in matched urothelial bladder cancer specimens.
    de Jong JJ; Stoop H; Nieboer D; Boormans JL; van Leenders GJLH
    Histopathology; 2018 Dec; 73(6):983-989. PubMed ID: 30003574
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Evaluation of PD-L1 and other immune markers in bladder urothelial carcinoma stratified by histologic variants and molecular subtypes.
    Li H; Zhang Q; Shuman L; Kaag M; Raman JD; Merrill S; DeGraff DJ; Warrick JI; Chen G
    Sci Rep; 2020 Jan; 10(1):1439. PubMed ID: 31996725
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Favorable prognostic impact of Natural Killer cells and T cells in high-grade serous ovarian carcinoma.
    Henriksen JR; Donskov F; Waldstrøm M; Jakobsen A; Hjortkjaer M; Petersen CB; Dahl Steffensen K
    Acta Oncol; 2020 Jun; 59(6):652-659. PubMed ID: 31931651
    [No Abstract]   [Full Text] [Related]  

  • 49. CD8 lymphocytes in tumors and nonsynonymous mutational load correlate with prognosis of bladder cancer patients treated with immune checkpoint inhibitors.
    Deng B; Park JH; Ren L; Yew PY; Kiyotani K; Antic T; O'Connor K; O'Donnell PH; Nakamura Y
    Cancer Rep (Hoboken); 2018 Jun; 1(1):e1002. PubMed ID: 32729250
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Low expression of TMEM67 is a critical predictor of poor prognosis in human urothelial carcinoma of the bladder.
    Du E; Zhang C; Qin Z; Yang K; Li C; Wang A; Zhang Z; Xu Y
    Urol Oncol; 2017 Apr; 35(4):152.e7-152.e12. PubMed ID: 28161324
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Systemic Immunotherapy of Non-Muscle Invasive Mouse Bladder Cancer with Avelumab, an Anti-PD-L1 Immune Checkpoint Inhibitor.
    Vandeveer AJ; Fallon JK; Tighe R; Sabzevari H; Schlom J; Greiner JW
    Cancer Immunol Res; 2016 May; 4(5):452-62. PubMed ID: 26921031
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical relevance and prognostic significance of PD-1/PD-Ls in non-metastatic bladder cancer: A role for PD-L2.
    Ariafar A; Ghaedi M; Rezaeifard S; Shahriari S; Zeighami S; Ghaderi A; Faghih Z
    Mol Immunol; 2020 Aug; 124():35-41. PubMed ID: 32512320
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Relationship Between PD-L1 Expression and CD8+ T-cell Immune Responses in Hepatocellular Carcinoma.
    Huang CY; Wang Y; Luo GY; Han F; Li YQ; Zhou ZG; Xu GL
    J Immunother; 2017; 40(9):323-333. PubMed ID: 29028787
    [TBL] [Abstract][Full Text] [Related]  

  • 54. PD-L1 expression and T cells infiltration in patients with uncommon EGFR-mutant non-small cell lung cancer and the response to immunotherapy.
    Chen K; Cheng G; Zhang F; Zhu G; Xu Y; Yu X; Huang Z; Fan Y
    Lung Cancer; 2020 Apr; 142():98-105. PubMed ID: 32120230
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Correlation Between Tumor Infiltration CD8+ T-cells And PD-L1 Expression In Laryngeal Cancer And Their Prognostic Significance: Prospective Non-interventional Trial.
    Ismail M; Shakweer MM; ElWakiel H; Abd El Ghany D; Gaballah A
    Gulf J Oncolog; 2021 Sep; 1(37):23-31. PubMed ID: 35152191
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinical Significance of PD-L1 Expression in Both Cancer and Stroma Cells of Cholangiocarcinoma Patients.
    Kitano Y; Yamashita YI; Nakao Y; Itoyama R; Yusa T; Umezaki N; Tsukamoto M; Yamao T; Miyata T; Nakagawa S; Okabe H; Imai K; Chikamoto A; Ishiko T; Baba H
    Ann Surg Oncol; 2020 Feb; 27(2):599-607. PubMed ID: 31407173
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Ovarian endometrioma infiltrating neutrophils orchestrate immunosuppressive microenvironment.
    Xu H; Zhao J; Lu J; Sun X
    J Ovarian Res; 2020 Apr; 13(1):44. PubMed ID: 32334621
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A high CD8 to FOXP3 ratio in the tumor stroma and expression of PTEN in tumor cells are associated with improved survival in non-metastatic triple-negative breast carcinoma.
    Tavares MC; Sampaio CD; Lima GE; Andrade VP; Gonçalves DG; Macedo MP; Cordeiro de Lima VC
    BMC Cancer; 2021 Aug; 21(1):901. PubMed ID: 34362334
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Overexpression of YAP 1 contributes to progressive features and poor prognosis of human urothelial carcinoma of the bladder.
    Liu JY; Li YH; Lin HX; Liao YJ; Mai SJ; Liu ZW; Zhang ZL; Jiang LJ; Zhang JX; Kung HF; Zeng YX; Zhou FJ; Xie D
    BMC Cancer; 2013 Jul; 13():349. PubMed ID: 23870412
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Impact of histological variants on oncological outcomes of patients with urothelial carcinoma of the bladder treated with radical cystectomy.
    Xylinas E; Rink M; Robinson BD; Lotan Y; Babjuk M; Brisuda A; Green DA; Kluth LA; Pycha A; Fradet Y; Faison T; Lee RK; Karakiewicz PI; Zerbib M; Scherr DS; Shariat SF
    Eur J Cancer; 2013 May; 49(8):1889-97. PubMed ID: 23466126
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.